CHRO קצב צמיחת רווח למניה בשנה הנוכחית Chromocell

The 12-month earnings per share growth rates on the GURU.Markets chart demonstrate current yields, where the value 0.00 captures the metric level. Chromocell Therapeutics (CHRO) builds intellectual capital through the study of ion channels for licensing purposes. The development of neuromedicine relies on partnerships with scientific centers to create analgesics. Currently, R&D resources are focused on trials of selective pain blockers.

This indicator measures the annual rate of change in net income per share, allowing for an assessment of return on equity dynamics. Analyzing the EPS YoY trajectory helps determine the resilience of cash flows to market volatility. The ratio of the current figure to the previous period reflects the effectiveness of Chromocell (CHRO) in monetizing its intellectual property in ion channels through licensing agreements with pharma behemoths.